New treatment option for irritable bowel syndrome with constipation and chronic idiopathic constipation.
作者信息
Schoenfeld Philip S
机构信息
Professor of Medicine Director, Training Program in Gl Epidemiology Division of Gastroenterology University of Michigan Medical School Ann Arbor, Michigan.
出版信息
Gastroenterol Hepatol (N Y). 2012 Dec;8(12):825-8.
Abstract
摘要
相似文献
1
New treatment option for irritable bowel syndrome with constipation and chronic idiopathic constipation.便秘型肠易激综合征和慢性特发性便秘的新治疗选择。
Gastroenterol Hepatol (N Y). 2012 Dec;8(12):825-8.
2
Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.普卡必利治疗慢性便秘和肠易激综合征。
Am J Med. 2019 May;132(5):572-575. doi: 10.1016/j.amjmed.2018.11.027. Epub 2018 Dec 11.
3
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.便秘型肠易激综合征和慢性特发性便秘的现有及新出现的治疗方法：聚焦于促分泌剂。
Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27.
4
Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.鲁比前列酮治疗慢性特发性便秘和肠易激综合征有效：随机对照试验的系统评价和荟萃分析
Mayo Clin Proc. 2016 Apr;91(4):456-68. doi: 10.1016/j.mayocp.2016.01.015.
5
Lubiprostone for constipation and irritable bowel syndrome with constipation.鲁比前列酮用于治疗便秘及便秘型肠易激综合征。
Expert Rev Gastroenterol Hepatol. 2008 Dec;2(6):727-33. doi: 10.1586/17474124.2.6.727.
6
Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older.评价普卡那肽治疗 65 岁及以上慢性特发性便秘和便秘型肠易激综合征患者的疗效。
Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10.
7
Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation.利那洛肽，一种治疗肠易激综合征和慢性便秘的新方向。
Curr Opin Mol Ther. 2007 Aug;9(4):403-10.
8
9
10
Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).使用确定性链接的行政索赔和患者报告数据对便秘型肠易激综合征和慢性特发性便秘患者进行综合评估：慢性便秘和肠易激综合征 C 型治疗和结局真实世界研究平台（CONTOR）。
J Med Econ. 2020 Oct;23(10):1072-1083. doi: 10.1080/13696998.2020.1799816. Epub 2020 Aug 11.
引用本文的文献
1
Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.抑制回肠胆汁酸转运体：慢性特发性便秘的一种新兴治疗策略。
World J Gastroenterol. 2015 Jun 28;21(24):7436-42. doi: 10.3748/wjg.v21.i24.7436.
本文引用的文献
1
Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.随机临床试验：linaclotide 在 IBS-C 中的 3 期研究 - 基于欧洲药品管理局规定终点的预先指定的进一步分析。
Aliment Pharmacol Ther. 2013 Jan;37(1):49-61. doi: 10.1111/apt.12123. Epub 2012 Nov 1.
2
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.一项为期 12 周、随机、对照试验，伴有 4 周的随机撤药期，旨在评估利那洛肽治疗便秘型肠易激综合征的疗效和安全性。
Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725. doi: 10.1038/ajg.2012.255.
3
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.Linaclotide 治疗便秘型肠易激综合征的 26 周随机、双盲、安慰剂对照试验：评估疗效和安全性。
Am J Gastroenterol. 2012 Nov;107(11):1702-12. doi: 10.1038/ajg.2012.254.
4
Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation.利那洛肽：其在肠易激综合征和慢性便秘中潜在应用的证据
Core Evid. 2012;7:39-47. doi: 10.2147/CE.S25240. Epub 2012 Jun 25.
5
Two randomized trials of linaclotide for chronic constipation.两项关于利那洛肽治疗慢性便秘的随机试验。
N Engl J Med. 2011 Aug 11;365(6):527-36. doi: 10.1056/NEJMoa1010863.
Zotero 插件